{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:28:37Z","timestamp":1790681317704,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MH44"],"award-info":[{"award-number":["ZR2021MH44"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Ocular toxoplasmosis (OT) is retinochoroiditis caused by <jats:italic>Toxoplasma gondii<\/jats:italic> infection, which poses a huge threat to vision. However, most traditional oral drugs for this disease have multiple side effects and have difficulty crossing the blood-retinal barrier, so the new alternative strategy is required to be developed urgently. Histone deacetylases (HDAC) inhibitors, initially applied to cancer, have attracted considerable attention as potential anti-<jats:italic>Toxoplasma gondii<\/jats:italic> drugs. Here, the efficacy of a novel HDAC inhibitor, Panobinostat (LBH589), against <jats:italic>T. gondii<\/jats:italic> has been investigated. <jats:italic>In vitro<\/jats:italic>, LBH589 inhibited the proliferation and activity of <jats:italic>T. gondii<\/jats:italic> in a dose-dependent manner with low toxicity to retinal pigment epithelial (RPE) cells. <jats:italic>In vivo<\/jats:italic>, optical coherence tomography (OCT) examination and histopathological studies showed that the inflammatory cell infiltration and the damage to retinal architecture were drastically reduced in C57BL\/6 mice upon treatment with intravitreal injection of LBH589. Furthermore, we have found the mRNA expression levels of inflammatory cytokines were significantly decreased in LBH589\u2013treated group. Collectively, our study demonstrates that LBH589 holds great promise as a preclinical candidate for control and cure of ocular toxoplasmosis.<\/jats:p>","DOI":"10.3389\/fcimb.2022.1002817","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T05:09:55Z","timestamp":1662959395000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["In vitro and in vivo anti\u2212Toxoplasma activities of HDAC inhibitor Panobinostat on experimental acute ocular toxoplasmosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijpddr.2020.12.003","article-title":"HDAC inhibitors tubastatin a and SAHA affect parasite cell division and are potential anti-toxoplasma gondii chemotherapeutics","volume":"15","author":"Araujo-Silva","year":"2021","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1167\/iovs.19-28306","article-title":"Neutrophil activities in human ocular toxoplasmosis: An in vitro study with human cells","volume":"60","author":"Ashander","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10792-012-9634-1","article-title":"Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: A prospective randomized clinical trial","volume":"33","author":"Baharivand","year":"2013","journal-title":"Int. Ophthalmol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: Emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1080\/09273948.2020.1737142","article-title":"Multimodal imaging in ocular toxoplasmosis","volume":"28","author":"Brandao-de-Resende","year":"2020","journal-title":"Ocul. Immunol. Inflammation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/09273948.2019.1569242","article-title":"Effectiveness of treatments for ocular toxoplasmosis","volume":"28","author":"Casoy","year":"2020","journal-title":"Ocul. Immunol. Inflammation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/ICB.0000000000000230","article-title":"Single acquisition of the vitreous, retina and choroid with swept-source optical coherence tomography in acute toxoplasmosis","volume":"10","author":"Chen","year":"2016","journal-title":"Retin. cases Brief Rep."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145977","article-title":"Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer","volume":"808","author":"Chen","year":"2022","journal-title":"Gene"},{"key":"B9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/09273948.2022.2086395","article-title":"Imaging ocular toxoplasmosis","volume":"30","author":"Cunningham","year":"2022","journal-title":"Ocul. Immunol. Inflammation"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00057-17","article-title":"Treatment of toxoplasmosis: Historical perspective, animal models, and current clinical practice","volume":"31","author":"Dunay","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijpddr.2015.05.004","article-title":"Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against plasmodium and trypanosoma parasites","volume":"5","author":"Engel","year":"2015","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2021.106180","article-title":"Ocular toxoplasmosis, an overview focusing on clinical aspects","volume":"225","author":"Fabiani","year":"2022","journal-title":"Acta Trop."},{"key":"B13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13643-021-01758-7","article-title":"Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis","volume":"10","author":"Feliciano-Alfonso","year":"2021","journal-title":"Syst. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1055\/s-0041-111821","article-title":"Ocular toxoplasmosis: An update","volume":"233","author":"Garweg","year":"2016","journal-title":"Klin. Monbl. Augenheilkd"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3390\/jcm10051090","article-title":"Treatment strategy in human ocular toxoplasmosis: Why antibiotics have failed","volume":"10","author":"Garweg","year":"2021","journal-title":"J. Clin. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00280-021-04313-2","article-title":"Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model","volume":"88","author":"Homan","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2016.1273865","article-title":"Mechanisms and pathways of toxoplasma gondii transepithelial migration","volume":"5","author":"Jones","year":"2017","journal-title":"Tissue Barriers"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.3390\/ijms23063254","article-title":"A histone deacetylase (HDAC) inhibitor with pleiotropic In vitro anti-toxoplasma and anti-plasmodium activities controls acute and chronic toxoplasma infection in mice","volume":"23","author":"Jublot","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10792-021-01994-9","article-title":"Ocular toxoplasmosis: A review of the current diagnostic and therapeutic approaches","volume":"42","author":"Kalogeropoulos","year":"2022","journal-title":"Int. Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1002\/cncr.33156","article-title":"Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia","volume":"126","author":"Karol","year":"2020","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00033","article-title":"In vitro evaluation of mannosylated paromomycin-loaded solid lipid nanoparticles on acute toxoplasmosis","volume":"10","author":"Khosravi","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/09273948.2013.823214","article-title":"Epidemiology, pathophysiology, and the future of ocular toxoplasmosis","volume":"22","author":"Kijlstra","year":"2014","journal-title":"Ocul. Immunol. Inflammation"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01088-19","article-title":"Therapeutic effects of intravitreously administered bacteriophage in a mouse model of endophthalmitis caused by vancomycin-sensitive or -resistant enterococcus faecalis","volume":"63","author":"Kishimoto","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41433-021-01491-4","article-title":"Distinguishing swept-source optical coherence tomography findings in active toxoplasmic retinochoroiditis","volume":"36","author":"Ksiaa","year":"2022","journal-title":"Eye (Lond)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/ceo.13453","article-title":"Effects of intravitreal bevacizumab in gram-positive and gram-negative models of ocular inflammation","volume":"47","author":"Lafreniere","year":"2019","journal-title":"Clin. Exp. Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00335-17","article-title":"A novel biomimetic nanosponge protects the retina from the enterococcus faecalis cytolysin","volume":"2","author":"LaGrow","year":"2017","journal-title":"mShere."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.1968257","article-title":"Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease","volume":"13","author":"Li","year":"2021","journal-title":"Gut Microbes"},{"key":"B28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106526","article-title":"A potent HDAC inhibitor blocks toxoplasma gondii tachyzoite growth and profoundly disrupts parasite gene expression","volume":"59","author":"Mouveaux","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1128\/IAI.68.1.407-410.2000","article-title":"Toxoplasma gondii infection induces gene expression and secretion of interleukin 1 (IL-1), IL-6, granulocyte-macrophage colony-stimulating factor, and intercellular adhesion molecule 1 by human retinal pigment epithelial cells","volume":"68","author":"Nagineni","year":"2000","journal-title":"Infect. Immun."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.104728","article-title":"Synthesis of nigranoic acid and manwuweizic acid derivatives as HDAC inhibitors and anti-inflammatory agents","volume":"109","author":"Ni","year":"2021","journal-title":"Bioorg. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000449169","article-title":"Recent developments in the diagnosis and treatment of ocular toxoplasmosis","volume":"57","author":"Ozgonul","year":"2017","journal-title":"Ophthalmic. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/IIO.0000000000000419","article-title":"Ocular toxoplasmosis: A review of current literature","volume":"62","author":"Patel","year":"2022","journal-title":"Int. Ophthalmol. Clin."},{"key":"B34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2217\/fon.09.36","article-title":"Panobinostat (LBH589): A potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors","volume":"5","author":"Prince","year":"2009","journal-title":"Future Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/1759-7714.12974","article-title":"Targeted inhibition of histone deacetylase 6 in inflammatory diseases","volume":"10","author":"Ran","year":"2019","journal-title":"Thorac. Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155643","article-title":"Local and systemic gene expression levels of IL-10, IL-17 and TGF-beta in active ocular toxoplasmosis in humans","volume":"146","author":"Raouf-Rahmati","year":"2021","journal-title":"Cytokine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1055\/a-1103-1900","article-title":"Class I and II histone deacetylase inhibitor LBH589 promotes endocrine differentiation in bone marrow derived human mesenchymal stem cells and suppresses uncontrolled proliferation","volume":"129","author":"Schroder","year":"2021","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100882","article-title":"Pathogenesis of ocular toxoplasmosis","volume":"81","author":"Smith","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/978-1-4939-9857-9_17","article-title":"Model systems for studying mechanisms of ocular toxoplasmosis","volume":"2071","author":"Smith","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1586\/eri.12.100","article-title":"Toxoplasma histone acetylation remodelers as novel drug targets","volume":"10","author":"Vanagas","year":"2012","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40262-017-0565-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of panobinostat","volume":"57","author":"Van Veggel","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02264","article-title":"Association of TREM-1, IL-1beta, IL-33\/ST2, and TLR expressions with the pathogenesis of ocular toxoplasmosis in mouse models on different genetic backgrounds","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Microbiol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1002817\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T05:09:59Z","timestamp":1662959399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1002817\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":42,"alternative-id":["10.3389\/fcimb.2022.1002817"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.1002817","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"article-number":"1002817"}}